In a recent report, HER2-targeted CAR-T cell confirmed its target potential, showed a similar line of efficacy against HER2+ tumors, including tumor regression or even elimination of CRC xenograft and protection of relapse, achieving improved survival benefit compared with the corresponding control group 34. Here, ERBB2 is linked to colorectal carcinoma.